Tiabendazole 500mg chewable tablets
2-Substituted benzimidazole first introduced in 1962.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 10 studies.
Randomised trials: 1 · 1988–2026
Showing all 10 studies, sorted by most relevant.
V. Fouresti�, M. E. Bougnoux, T. Ancelle, et al.
Parasitology Research, 1988
- Muscles
- Eosinophils
- Mice
Płatkiewicz J, Frankowski R, Grześkowiak T, et al.
2026
Conventional biological treatment in wastewater treatment plants (WWTPs) have demonstrated limited efficiency in removing contaminants of emerging concern. This study investigated the biodegradation of nine azole antifungals using activated sludge from two WWTPs. Nearly complete degradation was observed for ketoconazole (within 17 days) and climbazole (28 days). Clotrimazole and epoxiconazole exhibited notable differences in removal efficiency between two sludges, ranging from 45% to 76% and 50% to 87%, respectively. Moderate removal (39-66%) was observed for tebuconazole, flutriafol, and tiabendazole, while the lowest degradation occurred for imazalil (~ 30%) and fluconazole (~ 10%). Sorption studies revealed that bioadsorption played a major role in the removal of tiabendazole and clotrimazole with 37-40% and 33-38% of the initial amount of compounds adsorbed on activated sludge, respectively. A reduction in microbial metabolic activity and total organic carbon after one week is likely related to substrate depletion typical of batch experiments rather than loss of activated sludge functionality. Transformation product analysis confirmed the formation of several metabolites structurally similar to parent compounds, retaining the bioactive azole ring, with similar or slightly lower toxicity compared to initial azoles. These findings highlight the roles of biodegradation and sorption in the removal of azole fungicides in activated sludge systems and indicate the limited capacity of conventional treatment to fully eliminate these compounds and the potential ecological risks related to the presence of azoles and their degradation products in the environment.
Abstract licence: CC BY
Ayu Yuliatri Manafe, M. Laut, Aji Winarso
Jurnal Veteriner Nusantara, 2023
Soil Transmitted Helminth (STH) is an intestinal nematode which in its life cycle requires soil for the maturation process. STH infection is classified as neglected disease, which is an infection that is not noticed and is chronic in nature because it does not cause typical clinical symptoms and the effects are only seen in the long term. The purpose of this study was to determine chemical and non-chemical control of STH infection on ruminants in dry land of NTT. The method used is a qualitative descriptive method with a literature study approach. Based on the results of the study, it was found that the chemical control of STH infection on ruminants in the dry land of NTT is from the benzimidazole group because it is easy to obtain, easy to apply and has good effectiveness, some of which are albendazole, mebendazole, levamisole, piperazine, pyrantel pamoate, and tiabendazole. Meanwhile, non-chemical effective control of STH infection can use several types of plants, including Putri malu extract (Mimosa pudica Linn.), katuk leaf extract, basil leaf extract (Ocimum americanum Linn.), soursop leaf extract (Annona muricata L.), alamanda leaf extract (Allamanda cathartica L.), mango arumanis (mangifera indica L.), and moringa leaf (Moringaoleifera L.) which have been studied contain chemical compounds that are beneficial such as anthelmintics, namely saponins, mimosin and tannins.
Abstract licence: CC BY-SA
M. Gholami-Ahangaran, M. Bahmani, N. Zia-Jahromi
Asian Pacific Journal of Tropical Disease, 2012
V. Baliharová, Lenka Skálová, R. Maas, et al.
Journal of Pharmacy and Pharmacology, 2003
- Hepatocytes
- Cells, Cultured
- Tumor Cells, Cultured
Vincent Lönngren, Elisabet Holst, Bo Ljunggren
The Lancet Infectious Diseases, 2010
- Ancylostomatoidea
- Hookworm Infections
- Dermatitis
Pedro Huapaya, Yrma Espinoza, Alina Huiza, et al.
Anales de la Facultad de Medicina, 2013
OBJETIVO: Describir la experiencia del uso de ivermectina y tiabendazole en pacientes atendidos en el Instituto de Medicina Tropical “Daniel A. Carrión”- UNMSM. MATERIAL Y MÉTODOS: Durante los años 2001 y 2002, se administró ivermectina 0,2 mg/kg en dosis única a 22 pacientes (Grupo 1) o tiabendazole 25 mg/kg por 3 días a 20 pacientes (Grupo 2) con diagnóstico de Strongyloides stercoralis en heces. Se efectuó controles entre 20 y 40 días después de administrado el tratamiento. RESULTADOS: El promedio de edades fue 21,8 años (DE 22,6) para el grupo 1 y de 33,5 años (DE 14,2) para el grupo 2. Hubo 12 varones (54,5%) en el grupo 1 y 7 (35%) en el grupo 2. Ivermectina fue 100% eficaz, mientras que tiabendazole lo fue en 95%; sólo un caso requirió un segundo ciclo debido a la alta carga parasitaria inicial; el siguiente control fue negativo. Los síntomas más frecuentes fueron diarreas (71,4%), dolor cólico (61,9%) y dolor epigástrico (47,6%). Todos los pacientes manifestaron mejoría clínica luego del tratamiento. Sólo 2 casos (10%) del grupo 2 manifestaron leve sensación nauseosa durante el primer día del tratamiento, que remitió por completo al segundo día. CONCLUSIONES: Ambos medicamentos ratifican su eficacia y seguridad para ser utilizados en el tratamiento de Strongyloides stercoralis; es necesario disponer de ellos en el petitorio nacional.
Abstract licence: CC BY-NC-SA 4.0
Drugs Handbook 2012–2013, 2011
Julia Płatkiewicz, R. Frankowski, T. Grześkowiak, et al.
Processes, 2025
The objective of this study was to investigate the adsorption of 11 azoles (tebuconazole, ketoconazole, econazole, miconazole, fluconazole, clotrimazole, climbazole, flutriafol, epoxiconazole, tiabendazole, and imazalil) on natural and waste-derived sorbents such as ceramsite, perlite, pumice, sawdust, coconut fibers, heavy oil fly ash (HOFA), activated carbon, and silica gel. The results of adsorption efficiency for most sorbents varied depending on the azole compounds and their concentration. The highest adsorption for all tested compounds was obtained for activated carbon and heavy oil fly ash, reaching about 100% in both tested concentrations (0.2 mg L−1 and 0.02 mg L−1). The HOFA material was characterized in terms of elemental analysis (CHNS), confirming the elemental contents of 52% C, 0.65% H, 0.4% N, and 2.3% S. The specific surface area of HOFA was 11.2 m2 g−1, and scanning electron microscopy (SEM) results showed the spherical yet porous nature of the particles. Furthermore, the calculated adsorption isotherms demonstrated that for most tested azoles, the Dubinin–Radushkevich (D-R) isotherm best fits the data, with R2 = 0.93 or more, which is characteristic of porous carbon materials. The results highlight the significant potential of the tested HOFA sorbent for effectively removing azoles, as the tests performed showed that it was possible to remove these compounds with a concentration of up to 0.2 mg L−1 within an hour. This is particularly important because HOFA is an easily accessible waste material. Furthermore, the adsorption of azoles will not increase the cost of HOFA disposal when using the standard procedures currently applied to this waste.
Abstract licence: CC BY
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
1.2 hours
Mechanism
The precise mode of action of thiabendazole on the parasite is unknown, but it m…
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
1 to 2 hours
Half-life
1.2 hours
Metabolism
Elimination
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 978 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC D01AC06
ATC P02CA02
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Thiabendazole
Matched from: Tiabendazole
Additional database identifiers
Drugs Product Database (DPD)
9707
ChemSpider
5237
BindingDB
50121347
PDB
TMG
ZINC
ZINC000000073711
GenBank Gene Database
J01611
GenBank Protein Database
145263
UniProt Accession
FRDA_ECOLI
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2596
GenAtlas
CYP1A2
GeneCards
CYP1A2
GenBank Gene Database
Z00036
Guide to Pharmacology
1319
UniProt Accession
CP1A2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2595
GeneCards
CYP1A1
GenBank Gene Database
K03191
GenBank Protein Database
181276
Guide to Pharmacology
1318
UniProt Accession
CP1A1_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Linked open data from Wikidata (Q424986), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.